Physician profile
Tran Ly
NPI 1649422924
$397.63
in general payments reported to CMS, 2019-2025
7 companies · $25.52 in 2025
The $25.52 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $45.06 · 2021: $67.58 · 2024: $39.96 · 2025: $25.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $39.96 · Food and Beverage: $25.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $39.96 |
| Food and Beverage | $25.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $137.61 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.32 | 2019-2021 | |
| Abbott Laboratories | $65.48 | 2024-2025 | Freestyle Insulinx, Freestyle Libre 3 |
| Lilly USA, LLC | $45.48 | 2019 | |
| Janssen Biotech, INC. | $27.02 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.16 | 2021 | |
| Glaxosmithkline, LLC. | $18.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tran Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.